Navigation Links
CryoLife Receives FDA Clearance For Next Generation HeRO Device

ATLANTA, April 4, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a next generation HeRO (Hemodialysis Reliable Outflow) device.  The HeRO device is the only subcutaneous AV access solution clinically proven to maintain long-term access for end-stage renal disease (ERSD) hemodialysis patients with central venous stenosis.  CryoLife anticipates launching the next generation HeRO device during the fourth quarter of 2013 following scale up and validation of the manufacturing process.

The newly cleared version features an adaptor that provides the option to pair the HeRO device's proprietary venous outflow component with certain other available dialysis access grafts, including early access arterial grafts.  The current generation includes a standard ePTFE graft, which requires the placement of a temporary dialysis catheter for approximately 2-3 weeks until the graft incorporates into the surrounding tissue and can be used for hemodialysis access.  By design, early access grafts allow access in a matter of days, thus eliminating the need for an accompanying dialysis catheter.

"We are pleased to receive FDA clearance for our next generation HeRO device, which will provide our customers with the option of using a standard or early access arterial graft in conjunction with the device's proprietary venous outflow component," noted Steven G. Anderson , chairman, president and CEO of CryoLife.  "Early access grafts eliminate the need for temporary dialysis catheters, which are associated with increased risk of infection, further enhancing the clinical benefits of the HeRO device.  Over the next several months we will work to optimize and validate the manufacturing processes for this next generation system, which includes scaling up our manufacturing supply chain."

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S., certain countries in Europe, and Canada.  CryoLife's CryoValve® SG pulmonary heart valve, processed using CryoLife's proprietary SynerGraft® technology, has FDA 510(k) clearance for the replacement of diseased, damaged, malformed, or malfunctioning native or prosthetic pulmonary valves.  CryoLife's CryoPatch® SG pulmonary cardiac patch has FDA 510(k) clearance for the repair or reconstruction of congenital heart defects.  CryoLife's BioGlue® Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels.  BioGlue is also CE marked in the European Community for use in soft tissue repair and approved in Japan for use in the repair of aortic dissections.  Additional marketing approvals for BioGlue have been granted in several other countries throughout the world.  CryoLife, through its subsidiary Cardiogenesis Corporation, specializes in the treatment of coronary artery disease for severe angina using a laser console system and single use, fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR).  In addition, CryoLife and it's subsidiary Hemosphere, Inc. market the HeRO® device, which is a solution for end-stage renal disease in certain hemodialysis patients.  CryoLife distributes PerClot®, an absorbable powder hemostat, in the European Community and other select international countries.  CryoLife's BioFoam® Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical.

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations.  These statements include those regarding the anticipated timing of our launch of the next generation HeRO device.  Applicable risks and uncertainties include that we may not be able to complete the manufacturing scale-up and validation processes in time to allow for a fourth quarter launch of our next generation HeRO device.  CryoLife is also subject to the general risks associated with our business, including the risk factors detailed in our Securities and Exchange Commission filings, including our Form 10-K for the year ended December 31, 2012.  CryoLife does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site:



D. Ashley Lee

Executive Vice President, Chief Financial Officer

and Chief Operating Officer

Phone: 770-419-3355

The Ruth Group

Nick Laudico / Zack Kubow

646-536-7030 / 7020

SOURCE CryoLife, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
2. CryoLife Completes Acquisition of Hemosphere
3. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
4. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
5. CryoLife Reports 13% Revenue Growth for Second Quarter 2012
6. CryoLife Announces Initiation of Quarterly Cash Dividend
7. CryoLife Reports 13% Revenue Growth for Third Quarter 2012
8. CryoLife to Participate in Lazard Capital Markets 9th Annual Healthcare Conference
9. CryoLife Receives Expanded Indication for BioFoam in Europe
10. CryoLife Announces Release Date and Teleconference Call Details for 2012 Fourth Quarter and Year End Financial Results
11. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "Radioimmunoassay Market ... User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic ... - Global Forecast to 2020" report ... ) has announced the addition of the ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/25/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced ... the United States (U.S.) Food ... candidate to Humira ® (adalimumab). Amgen believes this ... the FDA and represents Amgen,s first BLA submission using ... , M.D., executive vice president of Research and Development ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... Indosoft Inc., developer and distributor of the world-class ... (Long Term Support) into its Q-Suite 5.10 product line. , Making the change ... version of Asterisk that will receive not only security fixes, but feature and ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... eReferral system for diagnostic imaging in the Waterloo region. Using the Ocean Platform, ... Medicine tests directly from their electronic medical record (EMR) without the need for ...
(Date:11/26/2015)... ... , ... Jobs in hospital medical laboratories and in the imaging field lead ... Aureus Medical Group . These fields, as well as travel nursing, ... healthcare jobs through the company’s website, , The leading healthcare staffing ...
(Date:11/26/2015)... ... 26, 2015 , ... Pixel Film Studios brings Final Cut ... Vintage. This newly styled ProTrailer pack comes with 30 all-new vintage-inspired designs, with ... users limitless opportunities to stylize and create designs quickly and easily, all within ...
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast ... found on mammography, according to a study published online in the journal Radiology. ... on mammography may necessitate a change in treatment. , Breast MRI is the ...
Breaking Medicine News(10 mins):